Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination
Syntocinon 的阿片类药物节省和减轻疼痛特性:剂量效应测定
基本信息
- 批准号:10543556
- 负责人:
- 金额:$ 17.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:Absence of pain sensationAcute PainAddressAffectAnalgesicsAnimal ModelAnimalsAreaBiochemistryBrainBrain regionBuprenorphineCardiovascular systemCorpus striatum structureDoseDouble-Blind MethodDrug PrescriptionsFormulationGoalsGrantHealthHeroinHourHumanImpairmentIndividualInflammationInterventionIntravenousLaboratory StudyLinkLiteratureManuscriptsMeasuresMechanicsMediatorMentorsMethadoneMorbidity - disease rateMorphineMotivationMusNeurobiologyNeuronsNeuropeptidesOpiate AddictionOpioidOpioid replacement therapyOralOxycodoneOxytocinPainPain DisorderPain MeasurementPain managementPathway interactionsPercocetPharmaceutical PreparationsPharmacotherapyPlacebo ControlPlacebo EffectPlacebosPrefrontal CortexPropertyPublic HealthRandomizedRattusRecreationReducing AgentsRegulationResearchRestRewardsScientific Advances and AccomplishmentsSelf AdministrationSensorySourceStandardizationStimulusStressStructureSupervisionSystemTechniquesTestingTranslationsWritingabuse liabilityaddictionanalogantinociceptionbehavioral economicsbehavioral pharmacologybrain pathwaybrain volumecareerchronic painconditioned place preferencehedonicinter-individual variationmortalitymultidisciplinarymultimodal neuroimagingmultimodalityneurobiological mechanismneuroimagingnovelnovel therapeuticsopioid abuseopioid epidemicopioid injectionopioid misuseopioid mortalityopioid overdoseopioid sparingopioid use disorderopioid useroverdose deathpain chronificationpain modelpain reductionpain sensitivitypre-clinicalpreservationpreventrespiratoryresponseskillssubstance use treatment
项目摘要
ABSTRACT
Opioid misuse is a major source of morbidity and mortality in the U.S. and represents a pressing public
health crisis. Opioid-related overdose deaths have more than quadrupled since 2002. Oxycodone (in
Percocet™ and Oxycontin™) is reliably among the medications commonly prescribed for pain, but is also widely
abused and involved in overdose deaths. Despite its abuse potential, oxycodone is effective for reducing acute
pain. There is an urgent need for interventions that preserve the analgesic properties of oxycodone while
curtailing its abuse potential. A promising adjunctive treatment option for pain management, that could
simultaneously reduce the abuse liability of opioids, is syntocinon (the intranasal formulation of the
neuropeptide oxytocin). Syntocinon may reduce opioid abuse potential, and simultaneously has
analgesic properties. Animal models have shown that oxytocin decreases opioid intravenous self-
administration and reverses oxycodone conditioned place preference. Rat models of pain show that oxytocin
enhances anti-nociception (blocking of painful stimuli), and in humans, syntocinon administration decreases pain
sensitivity experimentally. Further, evidence in animals and humans support the shared brain structure and
function changes associated with both addiction and chronic pain, which may be modulated by oxytocin
administration. Based on the existing literature, we propose that syntocinon will significantly reduce abuse
liability of opioids and reduce experimental pain via its effects on brain structure, function and
biochemistry. Thirty healthy recreational opioid users will self-administer 48 IUs of intranasal syntocinon (or
placebo) shortly after oral oxycodone (0, 2.5, 5.0 mg) in a double-blind, randomized, placebo-controlled, within-
subjects laboratory study. Subject-rated abuse liability and cardiovascular and respiratory responses will be
assessed before and repeatedly for 5 hours following drug administration. Pain and neurobiological measures
will also be collected, including a standardized experimental pain battery (i.e., quantitative sensory testing) and
a multi-modal neuroimaging battery (i.e., brain structure, function, and biochemistry). This study has
tremendous potential for public health impact in examining intranasal oxytocin as a promising agent for
reducing opioid addictive potential, while effectively reducing pain, which could substantially advance the field of
pharmacotherapy and carve out a novel treatment option. This study will also advance scientific understanding
of neurobiological mechanisms underlying the link between abuse potential and pain. This research will also
facilitate the PI’s career goals and path to independence by developing expertise in 1) multi-modal assessments
of pain; 2) neuroimaging techniques as they relate to addiction and pain; 3) deepen current expertise in addiction
and human behavioral pharmacology in the context of opioid administration and translation; 4) grant and
manuscript writing skills; and 5) enhance management and supervision skills. This multidisciplinary team is
uniquely suited to mentor the PI in these areas and address the proposed aims.
抽象的
阿片类药物滥用是美国发病率和死亡率的一个主要来源,也是公众迫切需要解决的问题
健康危机。自 2002 年以来,与阿片类药物相关的过量死亡人数增加了四倍多。 羟考酮(在
Percocet™ 和 Oxycontin™)是可靠的常用止痛药物之一,但也被广泛使用
被滥用并涉及过量死亡。尽管有滥用的可能性,羟考酮仍能有效减少急性发作
疼痛。迫切需要采取干预措施来保留羟考酮的镇痛特性,同时
减少其滥用潜力。一种有前景的疼痛管理辅助治疗选择,可以
同时减少阿片类药物的滥用倾向的是 Syntocinon(鼻内制剂)
神经肽催产素)。 Syntocinon 可能会减少阿片类药物滥用的可能性,同时具有
镇痛特性。动物模型表明,催产素可降低阿片类药物静脉注射的自我依赖性。
给药并逆转羟考酮条件性位置偏好。大鼠疼痛模型显示催产素
增强抗伤害感受(阻断疼痛刺激),在人类中,使用合产素可减轻疼痛
实验灵敏度。此外,动物和人类的证据支持共享的大脑结构和
与成瘾和慢性疼痛相关的功能变化,可能受到催产素的调节
行政。根据现有文献,我们建议缩宫素将显着减少滥用
阿片类药物的责任并通过其对大脑结构、功能和功能的影响来减轻实验疼痛
生物化学。 30 名健康的娱乐性阿片类药物使用者将自行施用 48 个国际单位的鼻内缩宫素(或
在一项双盲、随机、安慰剂对照、内部试验中,口服羟考酮(0、2.5、5.0 mg)后不久服用安慰剂)
科目实验室研究。受试者评定的滥用倾向以及心血管和呼吸系统反应将
给药前和给药后 5 小时内重复评估。疼痛和神经生物学测量
还将收集,包括标准化实验疼痛电池(即定量感官测试)和
多模式神经成像电池(即大脑结构、功能和生物化学)。这项研究有
检查鼻内催产素作为一种有前途的药物对公共卫生影响的巨大潜力
减少阿片类药物成瘾的可能性,同时有效减轻疼痛,这可以大大推进这一领域
药物疗法并开辟出一种新的治疗选择。这项研究还将促进科学理解
滥用潜力与疼痛之间联系的神经生物学机制。这项研究还将
通过发展 1) 多模式评估方面的专业知识,促进 PI 的职业目标和独立之路
疼痛; 2)与成瘾和疼痛相关的神经影像技术; 3)深化目前成瘾方面的专业知识
以及阿片类药物给药和翻译背景下的人类行为药理学; 4)授予和
稿件写作技巧; 5)提高管理和监督能力。这个多学科团队是
非常适合在这些领域指导 PI 并实现拟议的目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Meredith Berry其他文献
Meredith Berry的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Meredith Berry', 18)}}的其他基金
The potential of oxytocin to reduce opioid abuse liability and pain among older adults
催产素降低老年人阿片类药物滥用倾向和疼痛的潜力
- 批准号:
10667718 - 财政年份:2023
- 资助金额:
$ 17.69万 - 项目类别:
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination
Syntocinon 的阿片类药物节省和减轻疼痛特性:剂量效应测定
- 批准号:
10301508 - 财政年份:2022
- 资助金额:
$ 17.69万 - 项目类别:
相似海外基金
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
- 批准号:
10603436 - 财政年份:2023
- 资助金额:
$ 17.69万 - 项目类别:
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
- 批准号:
10778757 - 财政年份:2023
- 资助金额:
$ 17.69万 - 项目类别:
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
- 批准号:
10783106 - 财政年份:2023
- 资助金额:
$ 17.69万 - 项目类别:
Development of A Focused Ultrasound Device for Noninvasive, Peripheral Nerve Blockade to Manage Acute Pain
开发用于非侵入性周围神经阻断来治疗急性疼痛的聚焦超声装置
- 批准号:
10740796 - 财政年份:2023
- 资助金额:
$ 17.69万 - 项目类别:
Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data
使用基于移动健康数据的数学模型预测儿童镰状细胞病急性疼痛
- 批准号:
10599401 - 财政年份:2022
- 资助金额:
$ 17.69万 - 项目类别:
Non-Contingent Acute Pain Stress Drives Analgesic Protection in Rats.
非偶然急性疼痛应激驱动大鼠镇痛保护。
- 批准号:
575854-2022 - 财政年份:2022
- 资助金额:
$ 17.69万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Prefrontal Cortex Hemodynamic Responses to Mindfulness Meditation and Acute Pain
前额皮质血流动力学对正念冥想和急性疼痛的反应
- 批准号:
467076 - 财政年份:2021
- 资助金额:
$ 17.69万 - 项目类别:
Studentship Programs
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
- 批准号:
9979265 - 财政年份:2020
- 资助金额:
$ 17.69万 - 项目类别:
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
- 批准号:
10218273 - 财政年份:2020
- 资助金额:
$ 17.69万 - 项目类别:














{{item.name}}会员




